BLI801 (Braintree Laboratories, 1c080f)

BLI801 is an oral laxative developed by Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, for the treatment of non-idiopathic constipation, specifically constipation induced by medications such as opioids. The drug has been evaluated in multiple clinical trials, including Phase 2 and Phase 3 studies, to assess its safety and efficacy in adults experiencing fewer than three spontaneous defecations per week. As an investigational product from Braintree Laboratories—a company known for its expertise in gastrointestinal health and osmotic laxatives—BLI801 is designed to alleviate symptoms of chronic constipation by facilitating bowel movements, likely through an osmotic mechanism that increases intraluminal water content.

Other names

BLI801 LaxativeBLI-801 LaxativeBLI 801 Laxative